Terms: = Thyroid cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568 AND Treatment
3 results:
1. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract] [Full Text] [Related]
2. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Development of an Anti-NaPi2b (slc34a2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract] [Full Text] [Related]
